-

Endologix to Present at Upcoming LSI US ’24 Emerging Medtech Summit

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced that Matt Thompson, President and CEO, will present at the Life Science Intelligence (LSI) USA '24 Emerging Medtech Summit. Scheduled for March 20, 2024, at 10:55 am PT on Track 3, Thompson will offer insights into the company's innovative portfolio and its impact on vascular disease treatment.

Matt Thompson remarked, "At this pivotal juncture for Endologix, our involvement in the LSI US '24 Emerging Medtech Summit underscores our dedication to spearheading innovation in vascular disease. It's a privilege to highlight our pioneering solutions designed to enhance patient outcomes. The summit represents a unique platform for interaction with industry peers and thought leaders, enabling collaborations that are essential for shaping the future of healthcare."

About Endologix

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX®2 Endovascular AAA System, ALTO® Abdominal Stent Graft System, and the DETOUR™ System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, California. To learn more about Endologix, please visit https://www.endologix.com/.

Contacts

Sandy Prietto
949-595-7240
sprietto@endologix.com

Endologix LLC


Release Versions

Contacts

Sandy Prietto
949-595-7240
sprietto@endologix.com

More News From Endologix LLC

Endologix Announces 1000 patients treated with the DETOUR™ System

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced that 1,000 patients have now been treated with Percutaneous Transmural Arterial Bypass (PTAB) using the DETOUR System. This milestone includes patients in the DETOUR1 and DETOUR2 clinical studies as well as those treated post-commercial launch (July 2023). PTAB with the DETOUR System offe...

Endologix Appoints Andrew Davis as Chief Commercial Officer

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held global medical device company specializing in innovative therapies for vascular disease, is pleased to announce the appointment of Andrew Davis as its new Chief Commercial Officer, effective immediately. Andrew joins Endologix with an extensive background in commercial leadership, having most recently served as the Chief Commercial Officer at Silk Road Medical where he successfully spearheaded the go-to-market strategy for a groun...

Endologix Announces Leadership Transition

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held global medical device company specializing in innovative therapies for vascular disease, today announced a leadership transition. Dr. Matt Thompson will step down as President and Chief Executive Officer and take on a new role as Executive Vice President and Chief Medical Officer. Dr. John Liddicoat has been appointed as the new President and CEO, effective immediately. Richard Mott, Chairman of the Board stated: “We are thrilled...
Back to Newsroom